GBIM:OTCMKTS
GlobeImmune Inc
$0.00010
0.00%
(0.00) 1D
Set 29, 3:48:52 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa GBIM...
Mkt. cap
580.00
Avg. na dami
1.74K
Dami
0.00
Mataas nang 52-wk
$0.04
Mababa nang 52-wk
$0.00
Mga natitirang share
5.75M
Bilang ng mga empleyado
22
Mkt. cap
580.00
Avg. na dami
1.74K
Dami
0.00
Mataas nang 52-wk
$0.04
Mababa nang 52-wk
$0.00
Mga natitirang share
5.75M
Bilang ng mga empleyado
22
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
investingLive
·
14 oras ang nakalipas
S&P 500 analysis and forecast after the "AI bubble" panic
Bloomberg.com
·
1 araw ang nakalipas
S&P 500 Steady as Warsh Boosts Expectations of Rate Hold
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
24/7 Wall St.
·
5 araw ang nakalipas
You Bought VOO to Own the S&P 500. On $500,000, One Chipmaker Is $40,400 of It
Profile
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Tungkol sa GlobeImmune Inc
CEO-
Mga Empleyado22
ItinatagEne 1, 1995
HeadquartersLouisville, Colorado, Estados Unidos
Sektor-
Websiteglobeimmune.com